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p53 is a sequence-specific DNA-binding oligomeric protein that can activate transcription from promoters 
bearing p53-binding sites. Whereas the activation region of p53 has been identified within the amino 
terminus, the location of the specific DNA-binding domain has not been reported. Thermolysin treatment of 
p53 protein generates a stable protease-resistant fragment that binds with marked specificity to p53 
DNA-binding sites. Amino-terminal sequencing of the fragment located the thermolysin cleavage site to 
residue 91. Because the fragment does not contain the cdc2 phosphorylation site at Ser-315, we conclude that 
the the site-specific DNA-binding domain of p53 spans the central region of the protein. The vast majority of 
the mutations in oncogenically derived p53 proteins are located within this central portion of the molecule. 
Such mutant p53 proteins exhibit defective sequence-specific DNA-binding. Although thermolysin digestion 
of mutant p53 proteins generates proteolytic patterns that differ from wild-type protein, one mutant ested, 
His-273, generates a resistant fragment that migrates with a similar electrophoretic mobility to the wild-type 
protease-resistant fragment. Interestingly, although intact mutant His-273 protein binds to DNA at 20~ the 
thermolysin-resistant mutant fragment does not. In addition, the central protease-resistant, si e-specific 
binding region of wild-type p53 does not demonstrate nonspecific DNA-binding. Thus, although sequences 
outside of the central region of p53 contribute to both nonspecific DNA-binding and oligomerization, they are 
not required for sequence-specific DNA-binding. 
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The p53 gene encodes aprotein that can function to sup- 
press progression through the cell cycle in response to 
DNA damage (for review, see Hartwell 1992; Lane 1992; 
Prives and Manffedi 19931. Mutations in p53 can cause 
cells to become oncogenically transformed (for review, 
see Lane and Benchimol 1990; Levine et al. 1991}. The 
normal function of p53 is regulated, at least in part, by 
the ability of the protein to bind site specifically to DNA 
(for review, see Vogelstein and Kinzler 1992}. Mutation 
of the p53 gene is frequently found in many forms of 
human cancer (Nigro et al. 1989; for review, see Holl- 
stein etal. 19911, and the tumor-derived mutant p53 pro- 
teins that have been tested thus far do not bind specifi- 
cally to DNA in vitro (Bargonetti et. al. 1991; Kem et al. 
1991a). Wild-type p53 binds nonspecifically to DNA 
(Steinmeyer and Deppert 1988; Kern et al. 1991b), as well 
as specifically to diverse DNA sequences that contain 
forms of the consensus sequence 5'-Pu Pu Pu C (A/T) 
(T/AJ G Py Py Py-3' {El-Deity et al. 1992; Funk et al. 
1992}. Wild-type, but not mutant, p53 can activate tran- 
scription from constructs containing strong p53-binding 
sites both in vitro (Farmer et al. 19921 and in vivo (Funk 
et al. 1992; Kastan et al. 1992; Kern et al. 1992; Scharer 
and Iggo 1992; Zambetti et al. 19921. Therefore, there is 
a strong connection between p53 DNA binding and nor- 
mal p53 function. 
The p53 protein, which is phosphorylated at residues 
within the amino- and carboxy-terminal regions, is com- 
posed of three separate structural regions: an acidic pro- 
line-rich amino terminus that mediates transcriptional 
activation (Fields and Jang 1990; Raycroft et al. 1990; 
Unger et al. 1992}, a hydrophobic internal region, and a 
region within the carboxyl terminus that contains an 
oligomerization domain (Shaulian et al. 1992; 
Sturzbecher et al. 1992; Pavletich et al., this issue). 
Present in the central portion of the protein are four re- 
gions that are evolutionarily conserved within all verte- 
brate species examined (Soussi et al. 1990}. Additionally, 
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approaches using antibodies have suggested that the cen- 
tral region contains determinants hat regulate the con- 
formation of p53 (Hinds et al. 1987; Cook and Milner 
1990; Gannon et al. 1990). To date, the specific DNA- 
binding domain of p53 has not been identified. The mu- 
tant p53 proteins found in human cancer contain amino 
acid substitutions or deletions that fall within the cen- 
tral portion of p53 and tend to cluster within the four 
conserved regions (for review, see Hollstein et al. 1991). 
This, coupled with the fact that oncogenically derived 
mutant p53 proteins do not bind to DNA, suggests that 
the central domain of p53 may be important for DNA- 
binding activity. Additionally, SV40 large T antigen 
binds to the central region of p53 {Tan et al. 1986; Jen- 
kins et al. 1988; Ruppert and Stillman 1993)and, as such, 
inhibits the in vitro DNA-binding ability of the wild- 
type protein (Bargonetti et al. 1992). 
Because the DNA-binding property of p53 is central to 
the function of the protein, it is important to determine 
what region of the protein contains the sequence-specific 
DNA-binding domain. Because distinct domains of pro- 
teins are frequently resistant o broad-range proteases 
(Heinrikson 1977), we examined the binding of p53 pro- 
teolytic fragments to oligonucleotides containing strong 
p53-binding sites. Using thermolysin digestion as a 
means to generate p53 fragments we have found that a 
stable p53 proteolytic fragment, -27  kD in mass, main- 
tains marked sequence specificity for DNA binding. In 
addition, we have compared the protease cleavage prod- 
ucts generated from mutants with those seen with wild- 
type p53. In some cases, the fragments generated were 
very similar to wild type, whereas in others they were 
different. In addition to determining the site-specific 
DNA-binding domain of p53, our data address the vari- 
ability between different oncogenically derived mutant 
forms of p53. 
Results 
Proteolysis of human p53 yields a sequence-specific 
DNA-bmding fragment 
To define the region of p53 that binds to DNA, we tested 
the ability of a broad range protease, thermolysin, to gen- 
erate protein fragments capable of binding a strong p53 
DNA-binding sequence using the lectrophoretic mobil- 
ity shift assay (EMSA). Immunopurified wild-type hu- 
man p53 was treated with increasing quantities of the 
enzyme under DNA-binding conditions; subsequently, 
oligonucleotides containing the strong p53-binding site 
from the murine muscle creatine kinase promoter 
{MCK), identified by Zambetti et al. (1992), were added 
to each reaction mixture. These samples contained a suf- 
ficient amount of protein to be analyzed by SDS-PAGE 
to identify the p53 proteolytic fragments (Fig. 1A); ali- 
quots were then examined by EMSA to determine 
whether any of the proteolytic fragments could bind to 
DNA (Fig. 1B). The proteolytic fragments detected after 
digestion demonstrated that the higher levels of ther- 
molysin generated a single resistant p53 fragment mi- 
Figure 1. Proteolysis of human p53 yields a fragment that 
binds DNA. Human p53 (7 ixg l was digested with increasing 
amounts of thermolysin at37~ for 15 rain such that the ratios 
(wt/wt) of protease/p53 were 1:7, 1:3.5, 1:2.3, and 1:1.75 {lanes 
2--5, respectively), a2p-Labeled MCK oligonucleotide {1.5 pmole) 
was added to each reaction, and i cubation was continued at 
20~ for 30 rain. Aliquots of the reaction mixtures were then 
analyzed for p53 proteolytic digestion patterns (A} and DNA- 
protein complexes {B). {A) Proteolyzed products were solved 
on a 10% polyacrylamide g l followed by electrotransfer to ni- 
trocellulose and probing with pAb 240. ILane 1) Untreated p53; 
{lane M} prestained standards {molecular m ss m kD at left). {B) 
EMSA of the proteolysis product reaction mixtures on a 4% 
native gel. {Lanes 1-5) The same protease reaction mixtures 
show in A; {lane 0) no p53 protein. 
grating at ~27 kD by comparison with standard pre- 
stained polypeptides (Fig. 1A, lanes 4,5}. Although the 
detection of these fragments was by Western blot anal- 
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ysis with the p53-specific antibody pAb 240, silver stain- 
ing of gels containing such digests howed similar prod- 
ucts in this size range (e.g., see Figs. 4B and 6A). The 
EMSA of aliquots of these proteolysis reaction mixtures 
showed that the thermolysin-digested protein bound 
well to the oligonucleotide, demonstrating an affinity 
that was in the range of full length p53 (Fig. 1B, lanes 
2-5). It is interesting to note that the binding ability of 
the thermolysin treated protein increased with the 
higher levels of protease used. This was commensurate 
with the disappearance of larger detectable p53 frag- 
ments (cf. Fig. 1, A and B, lanes 2-5), and the appearance 
of smaller fragments (data not shown), suggesting the 
possibility that such fragments either mask or inhibit 
the DNA-binding ability of the major protease-resistant 
product. 
To further analyze the DNA-binding properties of the 
thermolysin-resistant fragment of p53 we examined its 
ability to bind to another strong DNA site for p53 from 
the human ribosomal gene cluster (RGC) identified by 
Kern et al. (1991). Previously, we have shown that p53 
binds with similar affinity to MCK and RGC (Bargonetti 
et al. 1992). In this experiment wild-type (RGC-W) and 
mutant (RGC-M) oligonucleotides were incubated with 
either full-length or thermolysin-treated p53 in the pres- 
ence of increasing amounts of competitor DNA poly[d(I- 
C)]; Fig. 2). EMSA analysis demonstrated that under the 
conditions of the binding assay, although full-length p53 
binding to RGC-W was clearly stronger, the protein was 
also capable of binding to RGC-M (Fig. 2, cf. lanes 9-11 
with lanes 2-4). In contrast, the thermolysin-digested 
p53, which demonstrated strong binding to RGC-W, dis- 
played virtually no detectable binding to RGC-M (Fig. 2, 
cf. lanes 12-14 with lanes 5-7). PhosphorImaging of the 
shifted DNA species howed that in the absence of com- 
petitor DNA the thermolysin-resistant fragment bound 
to RGC-W 50% as efficiently as full-length protein (Fig. 
2, cf. lanes 9 and 12). At the highest level of competitor 
DNA, full-length p53 bound to RGC-M 27% as effi- 
ciently as RGC-W (Fig.2, cf. lanes 4 and 11), whereas the 
p53 fragment bound RGC-M only 1% as efficiently as 
RGC-W (Fig. 2, cf. lanes 7 and 14}.The binding displayed 
by full-length p53 to RGC-M may be controlled by se- 
quences outside the central-core, thermolysin-resistant 
fragment. These findings indicate that the thermolysin- 
resistant p53 fragment displays strong sequence-specific 
DNA-binding activity and displays little nonspecific 
DNA-binding activity as compared with the full-length, 
wild-type protein. This suggests that when excised from 
the intact protein, the central region of p53 has lost some 
of the determinants hat stabilize DNA-binding. 
The ~27-kD thermolysin-resistant DNA-binding 
fragment spans the central region of p53 
The proteolytic p53 fragments hown in Figure 1 were 
detected by immunostaining with pAb 240. The epitope 
of pAb 240 has been mapped to residues 212-217 
(Stephan and Lane 1992}, suggesting that this region of 
p53 is contained within the DNA-binding portion. This 
Figure 2. The thermolysin-resistant p53 fragment binds se- 
quence specifically to DNA. Untreated p53 (3.5 ~g; lanes 2-4 
and 9-1 l J or p53 treated at 37~ for 30 min with thermolysin 
[1:1.75 wt/wt; lanes 5-7 and 12-14] were incubated with 25 ng 
of either RGC-M (lanes 2-7) or RGC-W (lanes 9-14) 32p labeled 
oligonucleotides in the presence of no competitor (lanes 
2,5,9,12), or 150 ng {lanes 3,6,I0, 13) or 300 ng (lanes 4,7,11, 14) 
of poly [d(I-C)]. Lanes I and 8 contain o p53 protein. 
is consistent with additional immunochemical data 
from Westem blot analysis, which showed that the -27- 
kD thermolysin-resistant p53 product lacks both the 
pAb 1801 epitope between 32 and 79 (Banks et al. 1986) 
at the amino terminus, and the pAb 421 epitope between 
residues 371 and 381 at the carboxyl terminus {Wade- 
Evans and Jenkins 1985); data not shown). Before obtain- 
ing further information about the sequence of the stable 
proteolytic p53 fragment, it was necessary to determine 
whether it was actually bound to DNA. This was accom- 
plished by isolating DNA-protein complexes containing 
either full-length or proteolyzed p53 from acrylamide 
gels, eluting the protein from such complexes, and ana- 
lyzing the eluted protein by SDS-PAGE (Fig. 3A). Be- 
cause the only polypeptide detectable in the therrnol- 
ysin-treated p53-DNA complex migrated as a fragment 
within the size range of 27-29 kD, the likelihood that 
this fragment contained the site-specific DNA-binding 
domain of p53 was high (for discussion of the size of the 
p53 fragment, see below). Accordingly, a larger prepara- 
tion of the the thermolysin-resistant product was gener- 
ated, electrophoresed on an SDS-polyacrylamide gel, 
electroblotted onto a polyvinylidene diflouride (PVDF) 
membrane, stained with Coomassie blue, and then 
amino-terminally sequenced by gas-phase analysis. The 
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Figure 3. The -27-kD thermolysin-resistant fragment spans he ce tral region f p53. {A) Intact or thermolysin-treated p53proteins 
were bound to s2P-labeled MCK oligonucleotide and DNA-protem complexes were resolved on a 4% native polyacrylamide gel. 
a2P-labeled bands corresponding to the shifted species (identified by wet autoradiography) were excised fromthe gel, and the protein 
was eluted. Shown here is a silver-stained 10% SDS-polyacrylamide g lwith the eluted polypeptides from the untreated- {lane 2) and 
the thermolysin-digested- (lane 3} p53. Lane I contains markers for size. {B) p53 protein was incubated for 30 rain with [~t-a2P]ATP and 
other reagents as described in Material and methods with {lanes 1-4) or without [lanes 5-8) cdc2 kinase before incubation with 
thermolysin. Subsequent thermolysin treatment ofp53 was at a ratio of 1:1.75 for 30 rain {lanes 2,5}, 45 rain {lanes 3,6), or 60 rain 
(lanes 4, 7) at 37~ Samples were analyzed by 15% SDS-PAGE, followed by electrotransfer to nitrocellulose and were probed with pAb 
240. {(2)) autoradiograph of the blot described in B. The arrowhead marks the position of the -27-kD thermolysin-resistant fragment 
detected in lanes 2-7 of B. 
sequence of the polypeptide LSSSVPSQKT identified the 
thermolysin cleavage site to be at amino acid 91. 
To gain information about the carboxyl terminus of 
the protease-resistant fragment, we took advantage of 
the single cdc2 kinase site on human p53 at Ser-315 
{Bischoff et al. 1990). The hall-length p53 was treated 
with purified cdc2 kinase and [7-a2P]ATP, and the la- 
beled protein was digested with thermolysin to generate 
the resistant fragment. After SDS-PAGE, electrotransfer 
to nitrocellulose, and Westem blotting with pAb 240 
{Fig. 3B), the blot was exposed to X-ray film to ascertain 
the location of the radioactive phosphate [Fig. 3C). The 
p53 preparation, when incubated alone with [V-a2p]ATP, 
displayed a small amount of endogenous-associated pro-
tein kinase activity [Fig. 3C, lane 8}. However, upon 
treatment with cdc2 kinase, the protein i corporated sig- 
nificantly more label [Fig. 3C, lane 1}. The highest level 
of thermolysin digestion, where the only species de- 
tected by Western blot analysis was the -27-kD frag- 
ment, also revealed a -14-kD species by autoradiogra- 
phy that was strongly labeled with ~/_a2p and several ad- 
ditional minor labeled species [Fig. 3C, lanes 2-4). 
PhoshorImaging showed that the minor labeled species 
were relatively insignificant when compared with the 
hall-length protein. Whereas the autoradiograph s owed 
that the labeled species in the vicinity of the position of 
the -27-kD polypeptide contained far less radioactivity 
than had been incorporated into hall-length p53 [Fig. 3, 
cf. B and C}, the Western blot demonstrated that an 
abundant quantity of the -27-kD thermolysin-resistant 
fragment had been generated {Fig. 3B, lanes 2-7). We 
therefore conclude that the p53 thermolysin-resistant 
fragment does not contain the Ser-315 site that was 
phosphorylated by edc2 kinase. Additionally, because 
human p53 contains a potential thermolysin cleavage 
site between Asn-306 and Leu-307, it is likely that Asn- 
306 is the carboxy-terminal mino acid of the DNA- 
binding fragment. The endogenously labeled p53 also 
yielded the -14-kD 7-a2P labeled material {Fig. 3C, lanes 
5-7) suggesting that the endogenous kinase phosphory- 
lates the protein at the carboxyl terminus. This is con- 
sistent with the fact that Herrman et al. {1991] have 
identified acasein kinase II activity associated with p53, 
and that casein kinase II was shown by Meek et al. (1990) 
to phosphorylate a single site at Ser-389. 
Taken together, our data with antibodies, amino-ter- 
minal sequencing, cdc2 kinase treatment, and relative 
SDS-PAGE migration show that the DNA-binding do- 
main of p53 is located within a protease-resistant frag- 
ment of p53 that extends from amino acid 91 to approx- 
imately amino acid 306. Thus, the specific DNA-binding 
domain resides within the central conserved portion of 
the protein. We first determined that the thermolysin- 
resistant p53 fragment has a molecular mass close to 
that of 27 kD by comparison with prestained markers, 
particularly with the 29-kD carbonic anhydrase marker 
polypeptide. However, in cases where the same digests 
were analyzed on gels containing unstained markers 
[such as that shown in Fig. 3A), the apparent migration of 
the single stable thermolysin-generated p53 fragment 
was somewhat closer to that of the 30-kD marker poly- 
peptide, indicating a somewhat greater molecular mass 
of -28 kD. Examination of the two kinds of standards 
run in adjacent wells on polyacrylamide gels showed 
that prestained markers migrate more slowly than their 
unstained counterparts, possibly ecause of the added 
mass of the dyes, thus explaining possible discrepancies 
between different experiments. Nevertheless, because 
the thermolysin-resistant fragment extends from residue 
91 at the amino terminus to, at the uppermost, residue 
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306 at the carboxyl terminus, thus containing a maxi- 
mum of 205 amino acids, this would correspond to a 
polypeptide with an actual molecular mass in the vicin- 
ity of 23-24 kD, rather than the estimated molecular 
mass of 27-28 kD that was derived from electrophoretic 
mobility. This discrepancy may be related to the fact 
that intact p53 itself, whose migration on gels would 
suggest hat it has a molecular mass of -53 kD, has an 
actual molecular mass of -44 kD. 
Proteolysis of mutant p53 proteins demonstrates 
variability in cleavage patterns 
We have constructed recombinant baculoviruses that ex- 
press tumor-derived mutant p53 proteins Ala-143, Trp- 
248, His-273, and His-175, with amino acid substitu- 
tions that are each located within a different conserved 
region. When assayed by DNase I footprinting, these mu- 
tant proteins did not exhibit site-specific DNA-binding 
ability (Bargonetti et al. 1992). It was therefore of interest 
to examine whether differences in the thermolysin 
cleavage patterns of the mutant proteins could be dis- 
cemed. Partial digestion of the immunopurified p53 pro- 
teins revealed that both the His-273 and Trp-248 mutant 
proteins have proteolytic pattems imilar (but not iden- 
tical) to wild-type protein {Fig. 4A, lanes 1-9). These two 
mutant proteins how additional similarity to wild-type 
p53 in that more xtensive proteolysis by thermolysin 
generates a stable fragment that also migrates at -27 kD 
in SDS-PAGE (Fig 4B, lanes 7-12). Partial proteolysis of 
the His-175 mutant p53 (Fig. 4A, lanes 10-12) demon- 
strated a proteolytic pattern substantially different from 
that of the wild-type protein; and after more extensive 
treatment virtually no His-175 p53 proteolytic frag- 
ments remained (Fig. 4B, lanes 13-15). The Ala-143 mu- 
tant protein also appeared to be consistently more sen- 
sitive to proteolysis; therefore, it was not possible to 
determine whether this mutant generated a partial pat- 
tern similar to or different from that of wild type (data 
not shown). However, it was clear that as with His-175 
p53, Ala-143 p53 did not yield a stable thermolysin-re- 
sistant fragment (Fig. 4B, lanes 4-6). These data, ob- 
tained with thermolysin treatment of mutant proteins, 
suggest hat His-273 and Trp-248 mutant p53 proteins 
maintain a structure similar to wild-type while Ala-143 
and His-175 mutant p53 proteins do not. 
The thermolysin product of His-273 mutant p53 
does not bind to DNA 
When we showed previously that the immunopurified 
mutant p53 proteins described above donot display se- 
quence-specific DNA-binding activity, the conditions 
used for those experiments included incubation of pro- 
teins and DNA at 37~ However, more recently we have 
found that some mutant p53 proteins bind to DNA at 
lower temperatures (Friedlander et al., unpubl.). The 
DNA-binding ability of one of these mutants, His-273, 
was compared with wild-type p53 by EMSA in both the 
absence and presence of competitor DNA at 20~ [Fig. 5). 
The wild-type and mutant p53 proteins displayed similar 
over-all binding when no competitor DNA was present 
(Fig. 5, cf. lanes 2 and 7). It should be noted that differ- 
ences in the wild-type and mutant p53 oligomeric forms 
associated with DNA were observed frequently. How- 
ever, when unlabeled competitor DNA was added there 
was a marked difference between the binding ability of 
the two proteins. As expected, wild-type p53 binding was 
strongly competed by the specific oligonucleotide 
RGC-W and very poorly competed by the mutant 
RGC-M (Fig. 5, lanes 8-11). In contrast, in the case of 
His-273, the unlabeled mutant oligonucleotide RGC-M 
Figure 4. Proteolysis of mutant p53 proteins demonstrates variability in the cleavage patterns. (A) Limited digestion of wild-type and 
mutant p53 proteins. Wild-type human p53 (lane 1), His-273 (lane 4), Trp:248 {lane 7}, and His-175 (lane 10) proteins (3 tLg) were 
digested with thermolysin at a protease top53 ratio (wt/wt) of 1:0.4 (lanes 2,5,8,11) or 1:0.2 (lanes 3,6,9,I2), respectively, for 30 rain 
at 20~ Samples were analyzed by 15% SDS-PAGE, followed by electrotransfer and immunoblotting with pAb240. (B) Extensive 
proteolysis of mutant p53 protein. Approximately i tLg of wild-type human p53 (lane 1), Ala-143 (lane 4), Trp-248 (lane 7), His-273 (lane 
10), and His-175 (lane 13)was digested with thermolysin at an enzyme/p53 ratio of 1:0.5 (lanes 2,5,8,11,14} or 1:0.25 (lanes 3,6,9,12,15} 
for 15 rain at 37~ Reaction mixtures were electrophoresed on a 15% SDS-PAGE, and the gel was silver-stained. Thearrowhead 
indicates the 35-kD thermolysin protein, which silver-stains negatively because it is a metaloprotease. 
GENES & DEVELOPMENT 2569 
 Cold Spring Harbor Laboratory Press on November 3, 2017 - Published by genesdev.cshlp.orgDownloaded from 
Bargonetti et al. 
D iscuss ion  
The p53 tumor suppressor protein can function as a 
checkpoint factor (Hartwell 1992), causing cells that 
were exposed to DNA-damaging agents to arrest in G1 
(Kastan et al. 1992; Hall et al. 1993). p53 presumably 
brings about this arrest, in part, by activating one or 
more genes that are part of a DNA damage-response 
Figure 5. The tumor-derived mutant p53 (His-273) binds DNA 
at 20~ EMSA, comparing the DNA binding of wild-type and 
mutant His-273 p53 proteins at 20~ Reaction mixtures con- 
tained 1.5 pmole of labeled MCK oligonucleotide and 1 txg of 
either His-273 {lanes 2-6) or wild-type {lanes 7-11 ) p53 with no 
competitor DNA {lanes 2,7), or 20 (lanes 3,8) or 40 (lanes 4,9) 
pmoles of unlabeled RGC-W competitor, and 20 {lanes 5,10) or 
40 {lanes 6,11) pmoles of unlabeled RGC-M competitor. Lane 1 
contains 1.5 pmoles of labeled MCK oligonucleotide with no 
p53 protein. 
was fairly effective at competing for binding to the la- 
beled probe (Fig. 5, of. lanes 5 and 6 with lanes 10 and 11). 
This result indicates that, although His-273 exhibits 
binding activity at 20~ as monitored by EMSA, the 
binding displayed is less specific than that demonstrated 
by wild-type p53. 
We then determined whether the thermolysin-resis- 
tant fragment of His-273 mutant p53 was capable of 
binding to the a2P-labeled MCK oligonucleotide (Fig. 6). 
The mutant protein yielded a predominant -27-kD mi- 
grating fragment hat was somewhat more resistant o 
proteolysis at 20~ than at 37~ (Fig. 6A). However, vir- 
tually no DNA binding by the mutant proteolytic digest 
was observed at either temperature (Fig. 6B, lanes 2-9). 
This was in marked contrast o the highly specific bind- 
ing displayed consistently by the wild-type p53 thermol- 
ysin fragment (e.g., see Fig. 2). Thus, although similar 
protease-resistant fragments are generated from both 
His-273 mutant and wild-type p53, only the wild-type 
fragment binds to DNA. The binding displayed by the 
intact His-273 mutant protein at 20~ appears to be of a 
significantly different nature from wild-type p53 and 
may be controlled, to some extent, by sequences outside 
the central-core thermolysin-resistant fragment. 
Figure 6. The thermolysin proteolytic fragment of mutant p53 
(His-273) does not bind to DNA. Thermolysin digestion of 1 ~g 
of mutant His-273 p53 was carried out at 20~ and 37~ as 
indicated with protease/p53 weight ratios of 1:0.5 (lanes 2,6), 
1:0.25 (lanes 3,7), 1:0.125 {lanes 4,8}, and 1:0.06 {lanes 5,9) for30 
rain. a2P-Labeled MCK oligonucleotide {1.5 pmole) was then 
added to each reaction mixture and incubated for 15 rain more. 
Half of each reaction mixture was either electrophoresed on a 
10% SDS-polyacrylamide geland then silver stained to detect 
the appearance of the -27-kD thermolysin-resistant fragment 
(A) or electrophoresed on a 4% acrylamide gel. The proportion 
of bound to free DNA was detected by autoradiography [B). 
{Lane 1) Full-length untreated p53; {lane O)no His-273 protein. 
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pathway. The fact that tumor-derived mutant p53 pro- 
teins do not activate transcription (Farmer et al. 1992; 
Kern et al. 1992) nor induce G1 arrest (Kastan et al. 1992) 
may contribute to the genetic instability that is a hall- 
mark of the oncogenic state (Livingstone t al. 1992; Yin 
et al. 1992). A key feature of transcriptional activation by 
p53 is the binding of the protein to DNA. Therefore, 
defining the region of p53 that is responsible for se- 
quence-specific DNA binding will further our under- 
standing of the normal function of p53. In this study we 
have isolated a thermolysin-resistant p53 fragment that 
exhibits strong sequence-specific DNA-binding activity 
in mobility shift assays. This fragment is the only poly- 
peptide detected in the DNA-protein complex isolated 
from acrylamide gels and is not immunoreactive in
Western blots with either the amino-terminal p53-spe- 
cific antibody pAb 1801 or the carboxy-terminal-specific 
antibody pAb 421. Gas-phase sequencing has determined 
that the amino-terminal c eavage site is at position 91, 
whereas treatment of intact p53 with cdc2 kinase and 
then cutting with thermolysin has demonstrated that 
the resistant fragment does not contain Set-315. These 
data locate the site-specific DNA-binding domain to 
within the central conserved region of the protein (see 
Fig. 7). Our findings are consistent with the work of Pav- 
letich et al. {this issue), showing that a bacterially ex- 
pressed p53 polypeptide able to bind to DNA contains 
amino acid residues 102 - 292. A feature that is common 
to all mutants tested is that they are defective in DNA 
binding. The fact that the vast majority of oncogenic 
mutations within p53 are located within the central por- 
tion of the protein fits extremely well with the location 
of the site-specific DNA-binding region that we have 
identified. Furthermore, our observation that SV40 T an- 
tigen, which was shown to bind to the central region of 
p53, abolishes pecific DNA-binding by p53 provides fur- 
ther support for our conclusions. 
Foord et al. (1991)proposed that the DNA-binding do- 
main of p53 is contained within the carboxy-terminal 83
amino acids of the protein. This was based on their ob- 
servation that truncated wild-type p53 lacking the car- 
boxy-terminal 83 amino acids was unable to bind to 
DNA. However, in that study they neither used a defined 
p53-binding sequence nor demonstrated directly that the 
missing 83 amino acids were capable of specifically bind- 
ing to DNA; therefore, their original conclusion must be 
reinterpreted. It is now clear that the specific DNA-bind- 
ing domain of p53 is not located within the extreme 
carboxyl terminus of the protein. Because p53 fragments 
containing sequences between residue 91 and 306 (this 
study), or Escherichia coli-expressed p53 polypeptide 102 
- 292 (Pavletich et al., this issue), or a baculovirus-ex- 
pressed p53 polypeptide containing residues 97--305 {Ja- 
yaraman et al., unpubl.) all bind specifically to p53 DNA- 
binding sites, it is evident hat the oligomerization do- 
main of p53 that is located within the carboxyl terminus 
(Sturzbecher et al. 1992; Pavletich et al., this issue) is 
also not required for p53 sequence-specific DNA-binding 
activity. However, the question must then be posed as to 
why some forms of p53 that are truncated at, or deleted 
within, the carboxyl terminus oligomerization region 
show defective DNA-binding ability despite the fact that 
they retain the DNA-binding domain (Foord et al. 1991; 
Hupp et al. 1992; Shaulian et al. 1993; Jayaraman et al., 
unpubl.). One explanation for this apparent discrepancy 
is that in the absence of an intact carboxy-terminal re- 
gion, the amino terminus may negatively regulate inter- 
actions by the central specific DNA-binding region. Pre- 
liminary experiments upport this possibility (Jayara- 
man et al., unpubl.). This would be akin to the 
observation that the p53 carboxy-terminal-specific anti- 
body pAb 421 activates p53 DNA binding (Funk et al. 
1992; Hupp et al. 1992; Halazonetis et al. 1993; J. Bar- 
gonetti et al., unpubl.) and that there is a negative regu- 
latory region within the extreme carboxy-terminal 30 
amino acids with repression of DNA-binding that can be 
relieved by various treatments {Hupp et al. 1992). Thus, 
discrete sequences outside of the central region of p53 
are capable of regulating the sequence-specific DNA- 
binding ability of the protein. Halazonetis et al. (1993) 
have suggested that the conformation of intact p53 
changes when the protein binds to DNA. The ability to 
assume this conformational change may be regulated by 
sequences both within and outside of the central DNA- 
binding region. 
The -27-kD thermolysin-resistant DNA-binding p53 
fragment contains four evolutionarily conserved regions 
that sustain a high occurrence of mutations in human 
cancers. The results from thermolysin digestion of the 
four mutant p53 proteins examined suggests that there 
dsDNA-PK and SEQUENCE-SPECIFIC DNA BINDING CDK site CKllsite 
CKI sites 
, ' 91 307 
ala143 his173 trp248 his273 Q 
lk * ik lk 
9 , I I I i = I , . - - . . - . J  
transcriptional activation 100 200 300 tetramerization regulation of 
region ,94 293j region DNA binding 
SV40 T antigen binding 
Figure 7. The central region of p53 binds to DNA. The lined area, spanning from 91 to306, indicates the structural domain of p53 
that binds sequence specifically to DNA. A detailed description of the diagram representing he structural domains of p53 is in Prives 
and Manfredi {1993). The five regions ofp53 that are evolutionarily conserved are shown a  stippled boxes; the asterisks {*) above them 
demark the substituted residues present in theoncogenic mutants described in this study. 
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may be at least two classes of mutations that cause ab- 
errant DNA binding. Two mutants, Trp-248 and His- 
273, generated thermolysin digestion patterns imilar to 
wild-type p53, suggesting that their structure is similar 
to wild type. If this is the case, then the inability of this 
class of mutants to bind to DNA may be attributable to 
changes in amino acids that make direct contact with 
the DNA. Interestingly Trp-248 and His-273 are tran- 
scriptionally active when fused to the GAL4 DNA-bind- 
ing domain (Raycroft et al. 1991), which lends support o 
the above possibility. The two other mutants tested, Ala- 
143 and His-175, were more highly susceptible to prote- 
olysis, suggesting that they might be less tightly folded. 
Consistent with this observation is the fact these two 
mutants are defective in trans-activation when fused to 
the GAL4 DNA-bindmg domain (Raycroft et al. 1991). 
Furthermore, Ala-143 and His-175 were reported to bind 
to the Hsc70 heat shock protein, whereas wild-type 53 
and His-273 do not (Hinds et al. 1990). 
Other lines of evidence point to the importance of the 
central region for DNA-binding activity. Xenopus p53, 
which is only homologous to human p53 in the central 
region, binds specifically to a human p53 consensus e- 
quence (Y. Wang and C. Prives, unpubl.). Additionally, 
thermolysin treatment of either Xenopus or murme p53 
protein yields a stable fragment hat complexes with a 
strong DNA-binding site (Y. Wang, J. Bargonetti, and C. 
Prives, unpubl.). Hainaut and Milner (1993) showed that 
metal ions bind to the conserved cysteinyl residues in 
this central region, and this binding stabilizes the ter- 
tiary structure of wild-type p53. Pavletich et al. {this is- 
sue) have shown that metal binding by p53 is necessary 
for the central region to exhibit DNA-binding activity. 
Although the central portion of p53 exhibits strong 
sequence-specific DNA-binding activity that is compa- 
rable to intact p53, it appears to have far less nonspecific 
DNA-binding activity han does the full-length protein. 
While full-length p53 was able to interact with a non- 
specific oligonucleotide, the -27-kD fragment was ex- 
tremely defective, suggesting that amino acids outside 
the central domain are important for nonspecific DNA- 
binding activity. The fact that His-273 mutant p53 was 
able to bind relatively nonspecifically to DNA when in- 
tact, but not when digested to yield the -27-kD frag- 
ment, also suggests that there are two determinants for 
DNA binding by p53. Shaulian et al. (1992) have reported 
that the carboxy-terminal portion of p53, extending from 
residue 302 to 390, is able to bind to DNA cellulose 
although it is unable to bind site specifically to DNA. 
Although oncogenic mutant p53 proteins cannot bind 
site specifically to DNA, perhaps many maintain the 
ability to bind nonspecifically to DNA in vivo. If so, this 
property might contribute to the role of mutant p53 pro- 
teins in cell transformation (Dittmer et al. 1993). The 
nonspecific DNA binding of mutant proteins, coupled 
with their ability to maintain interactions with other 
regulatory proteins, might incur promiscuous regulation 
of many promoters, thereby trans-activating genes that 
under normal circumstances would be inactive. If this 
were the case, inactivating the nonspecific DNA-binding 
2572 GENES & DEVELOPMENT 
activity of mutant p53 protein might be a means to in- 
activate some of the transformation activity demon- 
strated by these mutants in human tumors. 
Mater ia ls  and methods  
Purification of p53 proteins 
Recombinant baculoviruses expressing wild-type human p53 or 
mutant p53 proteins His-273, His-175, Ala-143 and Trp-248 
were described previously (Bargonetti et. al. 1992, and refer- 
ences therein}. Sf21 insect cells {2.Sx107/150-mm dish)were 
infected with recombinant viruses and harvested at 48 hr 
postinfection. Extracts of infected cells were prepared, and p53 
proteins were purified from cell lysates by immunoaffinity pro- 
cedures as described previously {Wang et. al. 1989). Protein 
A-Sepharose columns cross-linked with p53-specific monoclo- 
nal antibody pAb 421 {Harlow et. al. 1981) were used to purify 
p53 proteins. The proteins were eluted with pAb 421 epitope 
containing p53 peptide (KKGQSTSRHKK-OH) (Wade-Evans and 
Jenkins 1985) and dialyzed into a buffer containing 10 mM 
HEPES (pH 7.5), 5 mM NaC1, 0.1 mM EDTA, 1 mM DTT, and 
50% glycerol. 
Proteolytic digests of p53 proteins and DNA-binding assays 
Thermolysin digests of purified p53 proteins were carried out at 
either 37~ or 20~ in 50-p.1 reaction volumes containing 40 n~ 
creatine phosphate, 4 rnM ATP, 7 rnM MgC12, and 0.5 mM DTT 
at enzyme/protein ratios as indicated. Over the course of these 
experiments he activity ofthe thermolysin preparations varied 
and the ratio for digestion was changed accordingly. 
After protease treatment of p53, DNA was added as indicated. 
The synthetic double-stranded oligonucleotides used in this 
study {RGC-W, RGC-M, and MCK}~RGC-W; 5'-TCGAGTTG- 
CCTGGACTTGCCTGGCCTTGCC'ITI'FC-3'; RGC-M; 5'-TC- 
GAGTITAATGGACTTTAATGGCCITrAATYITC-3'; MCK; 
5'-TCGAGTGGCAAGCCTATGACATGGCCGGGGCCTGC- 
CTCTCTCTGCCTCTGACCCTC-3'--which were described 
previously {Bargonetti etal. 1992}, were labeled using the large 
fragment of DNA polymerase and [et-a2P]dNTPs. Reaction mix- 
tures {50 wl) containing 40 mM creatine phosphate, 4 mM ATP, 
7 mM MgCI2, 0.5 mM DTT, and labeled oligonucleotide (3 x 10-7 
M), as well as full-length or proteolytically-cleaved p53, were 
incubated at temperatures and for times as indicated. In some 
cases, unlabeled competitor poly [d(I-C}], RGC-W, or RGC-M 
was then added at indicated concentrations and the binding 
reaction was allowed to continue for the additional time as 
shown. The protein-DNA complexes were resolved by 4% na- 
tive acrylamide gel electrophoresis in a buffer of 0.5x Tris-bo- 
rate electrophoresis buffer (TBE). Each reaction mixture (10 ~1 
was electrophoresed on a 4% native gel for EMSA, and the re- 
mainder of each sample was analyzed by 10% or 15% SDS- 
PAGE. The gels were either silverstained or electrotransferred 
to nitrocellulose and probed with p53-specific antibody pAb 240 
{Galmon et al. 1990) or with a mixture of p53-specific antibodies 
[pAb 240, pAb 421, and pAb 1801 (Banks et al. 1986)]. 
Elution of protein ~rom native gels 
Elution of proteins from native acrylamide gels was essentially 
as described {Hager and Burgess 1980}. Full-length purified p53 
[7 ~g) or - 25 ~g of thermolysin-digested p53[at an enzyme to 
p53 ratio of 1: 1.75} was bound to 3 x 10 -7 M labeled MCK for 
EMSA analysis. The thermolysin-treated protein (a combina- 
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tion of four reaction mixtures loaded over four lanes) was elec- 
trophoresed on a 4% native gel, which was then exposed wet to 
X-ray film overnight at 4~ The gel slices corresponding to the 
shifted complexes were excised, crushed, and soaked in elution 
buffer containing 0.1 mM EDTA, 5 mM DTT, 0.20 M NaC1, 0.1% 
SDS, and 0.05 M Tris-HC1 {pH 7.9) for 3 hr at 25~ The crum- 
bled gel was pelleted in a clinical centrifugation for 1 rain at 
maximum speed, and the supematant was then transferred into 
a siliconized 15-ml Corex tube and precipitated with four vol- 
umes of ice cold acetone for 30 rain in a dry ice ethanol bath. 
After centrifugation at 10,000 rpm for 30 rain, protein-electro- 
phoresis ample buffer was used to resuspend the pelleted ma- 
terial and the samples were separated on a 10% SDS--polyacryl- 
amide gel. 
Amino-terminal sequence analysis of the p53 DNA-binding 
fragment 
Sequencing of the -27-kD thermolysin-resistant p53fragment 
amino terminus was as described (Matsudaira 1987). Purified 
wild-type human p53 (60 ~g)was digested with thermolysin ata 
ratio of 1:0.5 at 37~ for 30 rain. Unlabeled RGC-W oligonu- 
cleotide was added to the reaction mixture (400 ~1), and incu- 
bation was continued at room temperature for 30 rain. The 
reaction mixture was then concentrated in an Amicon concen- 
trator spun at 5000 rpm for 1 hr. The sample was then electro- 
phoresed on a 10% SDS-polyacrylamide gel and electrotrans- 
fered to a ProBlott membrane {Applied Biosystems). The mem- 
brane was stained with Coomassie blue to visualize the 
proteolyzed p53 product before amino-terminal sequence anal- 
ysis by the Protein Chemistry Core Facility {Columbia Univer- 
sity). Gas-phase sequencing was performed using an Applied 
Biosystems model 470A protein sequencer/120A PTH analyzer 
for 10 cycles. 
Phosphorylation of p53 
Phosphorylation f p53 was carried out by incubation of p53 at 
30~ for 30 rain in buffer containing 50 mM HEPES at pH 7.9, 10 
mM MgC12, 1 mM DTT, 0.1 mM ATP, and 25 ~Ci of [~/-a2P]ATP 
{New England Nuclear, 3000 Ci/mmole), in the absence or pres- 
ence of 0.8 ng of cdc2 kinase {sp. act. 912 nmoles/min per mgl 
purified from mitotic HeLa cells and characterized according to 
Marshak et al. ( 1991 ) 
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